Arformoterol tartrate

Arformoterol Tartrate is the tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol and a long-acting beta-2 adrenergic agonist with bronchodilator activity. Arformoterol selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to an inhibition of release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function. It is grouped under the following drug class(es): Beta-2 agonists. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Brovana, (R and R)-Arformoterol tartrate. Its PubChem CID is 9827062.